Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Earlier this month the Mathematics Institute at Uppsala University hosted a conference called Categorification in Algebra and Topology, clearly a theme close to our collective heart. As yet there are ...